CorMedix Shares Climb With Higher 1Q Profit, Sales

Dow Jones05-15

By Christopher Kuo

CorMedix shares rose after the company reported higher first-quarter profit and revenue.

Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.

The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.

Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.

"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand," said Chief Executive Joseph Todisco. "In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity."

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 14, 2026 14:44 ET (18:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635747065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635747065","market":"hk","top_or_hot":-1,"title":"CorMedix Shares Climb With Higher 1Q Profit, Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Climb With Higher 1Q Profit, Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Climb With Higher 1Q Profit, Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 02:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635747065","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635747065","pubTimestamp":1778784240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CorMedix shares rose after the company reported higher first-quarter profit and revenue.Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.\"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stag","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRMD":"CorMedix Inc."},"translate_title":"CorMedix股价上涨，第一季度利润和销售额增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n\n\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n\n\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n\n\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n\n\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 14:44 ET (18:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635747065","isCrawlerRequest":true}